Leading biotech in pathogen genome engineering
specializing in bacterial vaccine innovation
We are driving the transformation of bacterial vaccine development from empirical approaches to rational design
View More
15+
Pathogens Genome
Engineering
3
Genetically Engineered
Vaccine Platforms
9
Innovative Bacterial
Vaccine Pipelines
40+
Highly Qualified
Employees
2800m²
State-of-the-Art
Facilities
Technology
01
PathX
  • Proprietary pathogenic bacteria genome editing platform; one-stop solution for bacterial vaccine development.
View More
02
OMV Plus
  • Proprietary engineered OMV technology platform, enables next-generation OMV vaccine development with better efficacy, safety and lower costs.
View More
Pipeline
N. meningitidisN. gonorrhoeaeB. pertussisS. aureus
Our pipelines target multibillion-dollar vaccine market opportunities, with potential best-in-class profile and limited competition.
View More
Our pipelines target multibillion-dollar vaccine market opportunities, with potential best-in-class profile and limited competition.
View More
Partnership
Product Out-licensing
Co-Discovery / Development
R&D Collaborations / Services
News